Chorioretinal ischemia and angiogenic milieu following photodynamic therapy.
OBJECTIVE
To investigate the development of chorioretinal ischemia and expression of angiogenic factors following photodynamic therapy (PDT) in normal rat chorioretina.


METHODS
Pimonidazole (hypoxia marker) was intraperitoneally administrated 15 min before PDT (to identify the intra-PDT ischemia) and at 10 days and 20 days after PDT (to identify post-PDT ischemia) in 14 Brown-Norway rats (4 rats at each point and 2 rats serving as controls). After enucleation and cryosection at each point, immunohistofluorescent (IHF) staining for pimonidazole was evaluated with confocal scanning microscopy. In another 14 rats, the expression of angiogenic factors following PDT was demonstrated in PDT-irradiated normal chorioretina. Four rats were randomly selected at 3, 7, and 14 days following PDT with 2 rats serving as controls (verteporfin-/laser-). The expressions of vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF), and hypoxia-inducible factor (HIF)-1a were evaluated at each point. Diode laser (689 nm, 25 J/cm(2)) was irradiated before verteporfin infusion in the left eye (verteporfin-/laser+) and after infusion in the right eye (verteporfin+/laser+) in each experiment.


RESULTS
Intensity of pimonidazole uptake increased during PDT and at 10 and 20 days following PDT. The intensity of pimonidazole was the most pronounced immediately after PDT irradiation, but VEGF expression was rarely detected immediately after PDT. VEGF, IGF, and HIF-1a expression increased at 3 days and 7 days. At 14 days after PDT, the expression of VEGF was sustained, but that of IGF and HIF-1a was irregular.


CONCLUSIONS
These results show that significant chorioretinal ischemia develops in the irradiated area following PDT and that the ischemia is most pronounced during PDT irradiation. Along with post-PDT overexpression of angiogenic factors, this may be a mechanism contributing to PDT resistance or recurrence of chorioretinal neovascular lesions.
Moon
Jun Woong
JW
Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea.
Kim
Young Joo
YJ
Khwarg
Sang In
SI
Chung
Hum
H
Yu
Hyeong Gon
HG
D042501:Angiogenic Proteins / Q000378:metabolism*; D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D019084:Fluorescent Antibody Technique, Indirect; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism; D007511:Ischemia / Q000209:etiology* / Q000378:metabolism; D018613:Microscopy, Confocal; D009593:Nitroimidazoles / Q000378:metabolism; D010778:Photochemotherapy / Q000009:adverse effects*; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D051381:Rats; D011914:Rats, Inbred BN; D012164:Retinal Diseases / Q000209:etiology* / Q000378:metabolism; D012171:Retinal Vessels / Q000473:pathology*; D013002:Somatomedins / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D000077362:Verteporfin
D042501:Angiogenic Proteins; D015415:Biomarkers; D016207:Cytokines; C497444:Hif1a protein, rat; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D009593:Nitroimidazoles; D017319:Photosensitizing Agents; D011166:Porphyrins; D013002:Somatomedins; D042461:Vascular Endothelial Growth Factor A; C467498:vascular endothelial growth factor A, rat; D000077362:Verteporfin; C033815:pimonidazole